Tilray TLRY stock analysis #shorts

GSK is set­ting aside a mid-stage 24-va­lent pneu­mo­coc­cal vac­cine pro­gram for adults to in­stead fo­cus on a pre­clin­i­cal op­tion that cov­ers 30-plus va­lents, the com­pa­ny

Genentech’s Columvi will become available in the US in summer 2023. Credit: Coolcaesar / commons.wikimedia.org. Roche Group member Genentech has secured approval from the US

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) Hu­mana said Wednes­day that … Sign up